RecruitingPhase III🇵🇱 PolandFemale onlyEN original

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and * If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Pacjentka ma potwierdzony laboratoryjnie rak szyjki macicy.
  • Rak szyjki macicy jest nieuleczalny standardowymi metodami (operacja, radioterapia) i rozprzestrzenił się.
  • Zakażenie wirusem HIV jest dobrze kontrolowane przez leki.
  • Wirusowe zapalenie wątroby typu B lub C jest dobrze kontrolowane przez leki.

✗ Disqualifies

  • Pacjentka miała ciężkie problemy z oczami, które mogłyby utrudnić leczenie.
  • Pacjentka ma aktywne choroby zapalne jelit wymagające leków osłabiających odporność.
  • Pacjentka ma poważne, niekontrolowane choroby serca lub naczyń mózgowych.
  • Pacjentka otrzymała inne, nieokreślone w tym badaniu leczenie raka.

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 2, 2026
Sex
Female only

Therapies / drugs in trial

Locations (138)

Mount Sinai Comprehensive Cancer Center ( Site 6000)

Miami Beach, United States

Florida Cancer Specialists - East ( Site 7000)

West Palm Beach, United States

Winship Cancer Institute of Emory University ( Site 5005)

Atlanta, United States

Nancy N. & J.C. Lewis Cancer and Research Pavillion - Research Department ( Site 6005)

Savannah, United States

TRIALS 365 ( Site 6008)

Shreveport, United States

Minnesota Oncology Hematology, PA ( Site 8003)

Edina, United States

Women's Cancer Center of Nevada ( Site 6011)

Las Vegas, United States

Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 6009)

New York, United States

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 6001)

Tulsa, United States

Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8007)

Eugene, United States

Women & Infants Hospital ( Site 6003)

Providence, United States

University of Tennessee Medical Center ( Site 6012)

Knoxville, United States

Texas Oncology - DFW ( Site 8005)

Fort Worth, United States

Texas Oncology-The Woodlands ( Site 8000)

The Woodlands, United States

Texas Oncology - Northeast Texas ( Site 8002)

Tyler, United States

University of Virginia Cancer Center ( Site 6014)

Charlottesville, United States

Centro de Oncología e Investigación de Buenos Aires ( Site 0107)

Berazategui, Argentina

Instituto de Investigaciones Clinicas Mar del Plata ( Site 0105)

Mar del Plata, Argentina

Fundación Respirar ( Site 0101)

Belgrano, Argentina

Instituto Misionero del Cancer ( Site 0112)

Posadas, Argentina

Instituto de Oncologia de Rosario ( Site 0104)

Rosario, Argentina

Hospital Provincial del Centenario ( Site 0106)

Rosario, Argentina

Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0111)

La Rioja, Argentina

Medizinische Universitaet Wien ( Site 0302)

Vienna, Austria

Medizinische Universitat Graz ( Site 0303)

Graz, Austria

Medizinische Universitaet Innsbruck ( Site 0301)

Innsbruck, Austria

Uniklinikum Salzburg Landeskrankenhaus ( Site 0304)

Salzburg, Austria

Antwerp University Hospital ( Site 0407)

Edegem, Belgium

Cliniques Universitaires Saint-Luc ( Site 0402)

Brussels, Belgium

Grand Hopital de Charleroi ( Site 0404)

Charleroi, Belgium

UZ Gent ( Site 0406)

Ghent, Belgium

UZ Leuven ( Site 0401)

Leuven, Belgium

Hospital Araújo Jorge ( Site 0518)

Goiânia, Brazil

Liga Norte Riograndense Contra o Câncer ( Site 0513)

Natal, Brazil

Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0514)

Porto Alegre, Brazil

Hospital São Lucas da PUCRS ( Site 0516)

Porto Alegre, Brazil

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0511)

Barretos, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0512)

São José do Rio Preto, Brazil

IBCC - Instituto Brasileiro de Controle do Câncer ( Site 0517)

São Paulo, Brazil

Instituto Nacional de Câncer - INCA ( Site 0515)

Rio de Janeiro, Brazil

Sunnybrook Research Institute ( Site 0605)

Toronto, Canada

Princess Margaret Cancer Centre ( Site 0601)

Toronto, Canada

Centre Hospitalier de l'Université de Montréal ( Site 0616)

Montreal, Canada

McGill University Health Centre ( Site 0602)

Montreal, Canada

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0611)

Québec, Canada

CIUSSS de l Estrie Centre Hospitalier Universitaire de Sherbrooke ( Site 0604)

Sherbrooke, Canada

CIDO SpA-Oncology ( Site 0708)

Temuco, Chile

IC La Serena Research ( Site 0710)

La Serena, Chile

FALP ( Site 0701)

Santiago, Chile

Pontificia Universidad Catolica de Chile-CICUC ( Site 0706)

Santiago, Chile

Bradfordhill ( Site 0702)

Santiago, Chile

ONCOCENTRO APYS-ACEREY ( Site 0703)

Viña del Mar, Chile

Clinica Somer ( Site 0903)

Rionegro, Colombia

Centro Cancerológico del Caribe (CECAC) ( Site 0906)

Barranquilla, Colombia

Instituto Nacional De Cancerologia ( Site 0909)

Bogotá, Colombia

Oncomédica S.A.S ( Site 0905)

Montería, Colombia

Oncólogos del Occidente S.A.S. ( Site 0908)

Pereira, Colombia

Fakultní Nemocnice Brno ( Site 1003)

Brno, Czechia

Nemocnice AGEL Novy Jicin a.s. ( Site 1004)

Nový Jičín, Czechia

Fakultni nemocnice Ostrava ( Site 1005)

Ostrava, Czechia

Fakultni nemocnice Kralovske Vinohrady ( Site 1002)

Prague, Czechia

Vseobecna fakultni nemocnice v Praze-Gynekologicko-porodnicka klinika 1.LF a VFN ( Site 1001)

Prague, Czechia

CHU Strasbourg-Hautepierre ( Site 1207)

Strasbourg, France

Oncopole Claudius Regaud ( Site 1203)

Toulouse, France

Hopital Europeen Georges Pompidou ( Site 1210)

Paris, France

Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 1401)

Athens, Greece

Aretaieio Hospital Oncology Unit ( Site 1402)

Athens, Greece

ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1403)

Chaïdári, Greece

Országos Onkológiai Intézet ( Site 1603)

Budapest, Hungary

Debreceni Egyetem Klinikai Kozpont ( Site 1601)

Debrecen, Hungary

Mater Misercordiae University Hospital ( Site 1804)

Dublin, Ireland

Hillel Yaffe Medical Center ( Site 1903)

Hadera, Israel

Rambam Health Care Campus ( Site 1907)

Haifa, Israel

Carmel Hospital ( Site 1901)

Haifa, Israel

Shaare Zedek Medical Center ( Site 1905)

Jerusalem, Israel

Rabin Medical Center ( Site 1904)

Petah Tikva, Israel

Sourasky Medical Center ( Site 1902)

Tel Aviv, Israel

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 2009)

Meldola, Italy

CRO-IRCCS ( Site 2014)

Aviano, Italy

Ospedale Humanitas San Pio X ( Site 2013)

Milan, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 2008)

Milan, Italy

ASST Spedali Civili ( Site 2001)

Brescia, Italy

Ospedale Cannizzaro ( Site 2010)

Catania, Italy

Istituto Europeo di Oncologia ( Site 2003)

Milan, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 2012)

Roma, Italy

Azienda Ospedaliera Ordine Mauriziano di Torino ( Site 2006)

Torino, Italy

Aichi Cancer Center ( Site 2114)

Nagoya, Japan

Kurume University Hospital ( Site 2112)

Kurume, Japan

Gunma Prefectural Cancer Center ( Site 2109)

Ōta, Japan

National Hospital Organization Hokkaido Cancer Center ( Site 2108)

Sapporo, Japan

Hyogo Cancer Center ( Site 2118)

Akashi, Japan

Iwate Medical University Hospital ( Site 2116)

Shiwa-gun, Japan

Kanagawa Cancer Center ( Site 2121)

Yokohama, Japan

University of the Ryukyus Hospital ( Site 2117)

Ginowan, Japan

Saitama Medical University International Medical Center ( Site 2106)

Hidaka, Japan

Shizuoka Cancer Center ( Site 2104)

Sunto-gun,, Japan

Cancer Institute Hospital of JFCR ( Site 2119)

Koto, Japan

The Jikei University Hospital ( Site 2107)

Minato, Japan

National Hospital Organization Kyushu Cancer Center ( Site 2102)

Fukuoka, Japan

Niigata Cancer Center Hospital ( Site 2110)

Niigata, Japan

Okayama University Hospital ( Site 2101)

Okayama, Japan

Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 2111)

Osaka, Japan

CANCER TREAMTENT CLINIC AND CLINICAL TRIALS SA DE CV ( Site 2204)

Guadalajara, Mexico

Grupo Médico ASSET ( Site 2203)

Mexico City, Mexico

Higiea Oncologia ( Site 2205)

Mexico City, Mexico

Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 2202)

Monterrey, Mexico

Scientia Investigacion Clinica S.C. ( Site 2201)

Chihuahua City, Mexico

Centro de Investigacion Clinica de Oaxaca ( Site 2207)

Oaxaca City, Mexico

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2605)

Warsaw, Poland

Narodowy Instytut Onkologii - Oddzial w Gliwicach-III Klinika Radioterapii i Chemioterapii ( Site 2604)

Gliwice, Poland

Mazowiecki Szpital Wojewódzki w Siedlcach ( Site 2601)

Siedlce, Poland

Swietokrzyskie Centrum Onkologii. ( Site 2602)

Kielce, Poland

Hopelands Cancer Centre ( Site 2816)

Hilton, South Africa

National Cancer Center ( Site 2905)

Goyang-si, South Korea

Seoul National University Hospital ( Site 2901)

Jongno-gu, South Korea

Severance Hospital Yonsei University Health System ( Site 2902)

Seodaemun-Gu, South Korea

Asan Medical Center ( Site 2904)

Seoul, South Korea

Samsung Medical Center ( Site 2903)

Seoul, South Korea

Institut Català d'Oncologia (ICO) - Girona ( Site 3002)

Girona, Spain

Hosp Clinico Universitario de Valencia ( Site 3001)

Valencia, Spain

Hospital Universitari Vall d Hebron ( Site 3003)

Barcelona, Spain

Hospital Universitario Reina Sofia ( Site 3006)

Córdoba, Spain

Hospital Ramon y Cajal ( Site 3005)

Madrid, Spain

Hospital Universitario 12 de Octubre ( Site 3007)

Madrid, Spain

Hospital Universitario La Paz ( Site 3004)

Madrid, Spain

Skanes Universitetssjukhus Lund ( Site 3103)

Lund, Sweden

Karolinska Universitetssjukhuset-Solna ( Site 3102)

Stockholm, Sweden

Linköping University Hospital ( Site 3101)

Linköping, Sweden

National Taiwan University Hospital ( Site 3301)

Taiwan, Taiwan

Taichung Veterans General Hospital ( Site 3304)

Taichung, Taiwan

National Cheng Kung University Hospital ( Site 3308)

Tainan, Taiwan

Mackay Memorial Hospital ( Site 3303)

Taipei, Taiwan

Chang Gung Memorial Hospital ( Site 3302)

Taoyuan, Taiwan

Chulalongkorn University ( Site 3403)

Bangkok, Thailand

Ramathibodi Hospital ( Site 3404)

Bangkok, Thailand

Faculty of Medicine Siriraj Hospital ( Site 3401)

Bangkok, Thailand

Maharaj Nakorn Chiang Mai Hospital ( Site 3402)

Chiang Mai, Thailand

The Christie Hospital NHS Foundation Trust ( Site 3602)

Withington, United Kingdom

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.